Application of histone methyltransferase EZH2 in preparation of biomarker for diagnosing sepsis

A technology of methyltransferase and sepsis, applied in the field of bioengineering, can solve the problems that cannot be used for sepsis treatment, lack of sensitivity and specificity, etc.

Inactive Publication Date: 2020-07-14
SHANGHAI EAST HOSPITAL EAST HOSPITAL TONGJI UNIV SCHOOL OF MEDICINE
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Biomarkers that have received widespread clinical attention include C-reactive protein (CRP), procalcitonin (PCT), blood lactate, IL-6, leukocyte DR antigen (HLA-DR), polysaccharide-binding protein (LBP), myeloid Cell tri

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of histone methyltransferase EZH2 in preparation of biomarker for diagnosing sepsis
  • Application of histone methyltransferase EZH2 in preparation of biomarker for diagnosing sepsis
  • Application of histone methyltransferase EZH2 in preparation of biomarker for diagnosing sepsis

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0021] Example 1 Comparison of EZH2 expression on T lymphocytes between sepsis and healthy controls

[0022] Compared with the healthy control group, the positive rate of EZH2 expression in lymphocytes and the average fluorescence intensity of sepsis patients increased significantly (such as figure 1 ). Compared with the healthy control group, EZH2 has CD4 in peripheral blood of patients 1, 3, and 7 days + The positive rate on lymphocytes increased significantly (P <0.001); its expression intensity is also significantly increased (P <0.001).

[0023] We further detected and analyzed the CD8 of EZH2 in patients with sepsis + The expression on lymphocytes showed that both the positive rate and the average fluorescence intensity were significantly higher than the control group. For further analysis on the first, third, and seventh days of the sepsis patient group, the positive rate of EZH2 on CD4+ T lymphocytes on the seventh day was significantly higher than that on the first day (P ...

Example Embodiment

[0025] Analysis of independent risk factors for death in 328 days

[0026] The single factor logistic regression analysis was performed according to the indicators that were statistically different between the death group and the survival group in the sepsis group. The single factor statistically significant indicators were then subjected to multi-factor logistic regression analysis. Participated in the multi-factor regression analysis index. Combined with the results of the test, an independent risk factor for 28-day death was obtained, which was the use of ventilator (OR: 4.107 (1.168-14.436).p = 0.028) and APACHEII (OR: 1.440 (1.159-1.791) on the first day of sepsis patients. ), p=0.001), SOFA (OR:1.495(1.168-1.915), p=0.001), CD8 + Percentage of T lymphocytes (%) (OR: 1.114 (1.008-1.231), p = 0.034), CD8 + T lymphocyte EZH2 + The average fluorescence intensity (OR: 1.022 (1.002-1.043), p = 0.032); (as shown in Table 3.1), the indicators were included in the ROC curve analysis...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of histone methyltransferase EZH2 in preparation of a biomarker for diagnosing sepsis severity or prognosis. The invention also provides a kit for diagnosing sepsis severity or prognosis. The kit contains a reagent for detecting histone methyltransferase EZH2 in a body fluid sample. The invention finds that the expression quantity of EZH2 in peripheral blood Tcells of a clinical sepsis patient is obviously higher than that of EZH2 in a healthy examinee; the SOFA score of the sepsis patient is positively correlated; through ROC curve analysis, it is foundthat the expression level of EZH2 in T cells can be used as a new biomarker for predicting sepsis prognosis, EZH2 is provided as an index for diagnosis, prognosis and treatment monitoring of sepsis infection, and the severity of sepsis can be evaluated.

Description

technical field [0001] The invention belongs to the field of bioengineering and relates to a biomarker, specifically the use of histone methyltransferase EZH2 in preparing a biomarker for diagnosing sepsis. Background technique [0002] Sepsis is a systemic inflammatory response syndrome caused by infectious factors accompanied by acute organ dysfunction. Some patients with sepsis who are still accompanied by uncorrectable persistent hypotension after adequate fluid resuscitation will further develop into septic shock. With the aging of the population and the increase of invasive medical methods, the incidence of sepsis continues to rise. Every year, millions of sepsis patients are added worldwide, of which more than 1 / 4 of the patients die. One, and the cost of treatment is expensive (more than 80,000 yuan per case in my country on average), which has caused a heavy economic burden on patients, families and society, so early diagnosis and treatment of sepsis and its complic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/573G01N21/64
CPCG01N33/573G01N33/56972G01N21/6428G01N2800/26G01N2800/52
Inventor 唐伦先孙宏包晓玮赵冬旸刘娜周如女许明正李珂吕迪宇白建文
Owner SHANGHAI EAST HOSPITAL EAST HOSPITAL TONGJI UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap